Tier 2 — strong

Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial on feasibility and tolerability

Anoop Nambiar, Dean Kellogg, Jaime Justice, Martin Goros, Jonathan Gelfond, Rodolfo Pascual, Shahrukh Hashmi, Michal Masternak, Larissa Prata, Nathan LeBrasseur, Andrew Limper, Stephen Kritchevsky, Nicolas Musi, Tamara Tchkonia, James Kirkland
EBioMedicine 2023 90:104481

Bibliography

PubMed
PMID 36857968
PubMed Central
PMC10006434
DOI
10.1016/j.ebiom.2023.104481
Funding
Reported funding/support: This work was supported by 10.13039/100000002National Institutes of Health grants R33AG61456 (JLK, TT), Robert and Arlene Kogod (JLK, TT), the Connor Fund (JLK, TT), Robert J. and Theresa W. Ryan (JLK, TT), and the 10.13039/100016997Noaber Foundation (JLK, TT) San Antonio Claude D. Pepper Older Americans Independence Center’s (OAIC)Pilot/Exploratory Studies Core (PESC) Grant (AMN, NM); NIHK01 AG059837 (JNJ), P30 AG021332 (SBK, JNJ); 10.13039/100000002NIHR37 AG013925 (JLK), the Connor Group (JLK), Glenn/10.13039/100000965AFAR BIG Award (JLK), Robert J. and Theresa W. Ryan (JLK), and the Noaber and Ted Nash Long Life Foundations (JLK).
Competing interests
Reported disclosure: Declaration of interests TT and JK have a financial interest related to this research including patents and pending patents on senolytic drugs, and their uses are held by Mayo Clinic. This research has been reviewed by the Mayo Clinic Conflict of Interest Review Board and was conducted in compliance with Mayo Clinic Conflict of Interest policies.

Study snapshot

DesignRandomized single-blind placebo-controlled phase 1 pilot
ModelHuman intervention research
Sample12 adults with idiopathic pulmonary fibrosis
InterventionDasatinib 100 mg/day plus quercetin 1,250 mg/day, 3 consecutive days/week
Duration3 weeks
EndpointsSource-specific outcomes described in the key findings

What the study showed, in plain terms

Published in 2023, this source examined senescence and longevity. Design: Randomized single-blind placebo-controlled phase 1 pilot. Sample/model: 12 adults with idiopathic pulmonary fibrosis. The exposure or intervention was Dasatinib 100 mg/day plus quercetin 1,250 mg/day, 3 consecutive days/week. Follow-up or treatment period: 3 weeks.

Scheduled dosing and assessments were completed. Nonserious adverse events were more frequent with D+Q, and functional outcomes did not differ meaningfully.

Pilot designed for feasibility and tolerability, not powered efficacy. Prescription combination effects cannot be attributed to quercetin alone.

Continue with Quercetin Data Center

For topic-level interpretation, read Is Quercetin a Senolytic? Human Evidence vs Longevity Claims. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Scheduled dosing and assessments were completed.
  • Nonserious adverse events were more frequent with D+Q, and functional outcomes did not differ meaningfully.
  • The recorded outcome domains were Source-specific outcomes described in the key findings.
  • The result applies to the tested exposure: Dasatinib 100 mg/day plus quercetin 1,250 mg/day, 3 consecutive days/week; 3 weeks.

What this study can and cannot tell us

  • Pilot designed for feasibility and tolerability, not powered efficacy. Prescription combination effects cannot be attributed to quercetin alone.
  • An individual controlled trial must be interpreted alongside its comparator, sample size, endpoint selection and independent replication. It does not validate a different commercial formulation or a general longevity claim.
  • Source basis: Source check: accessible full text and indexed metadata. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
Senolytics dasatinib and quercetin in metabolic dysfunction-associated steatohepatitis: a proof-of-principle randomized, controlled trial
Mijra Koning et al. · Nature metabolism · 2026
Tier 2
Evaluation of exploratory fluid biomarkers from a phase 1 senolytic trial in mild Alzheimer's disease
Valentina R Garbarino et al. · Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025
Tier 2
Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women: a phase 2 randomized controlled trial
Joshua N Farr et al. · Nature medicine · 2024

Citation network

Articles citing this research paper

1 article

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology